Tuesday, July 1, 2025 7/1/2025

Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder

Award Number: R43DA053010
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder - Vivreon Biosciences – RFA-19-019 Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder Project Summary Vivreon Biosciences is pleased to apply for NIDA RFA-19-019. Vivreon Biosciences is an innovative life sciences company that is developing novel small molecule, Ca2+ channel inhibitors for the treatment of opioid use disorder (OUD). Our candidate therapeutics target brain microglial cells by an entirely new mechanism – inhibition of Ca2+ release-activated Ca2+ (CRAC) channels to block microgliosis. Vivreon seeks NIDA funding to perform preclinical proof of concept studies to test its preclinical lead, VV7063, in an animal model of opioid use disorder (OUD) and validate the CRAC channel as a therapeutic target for opioid withdrawal. Upon successful completion of this grant, Vivreon will identify a novel, non-opioid target for OUD. Future funding will be aimed at improving drug- like properties of Vivreon’s preclinical lead to identify the first ever CRAC-targeted clinical candidate for opioid withdrawal, providing an entirely new tool in the battle against OUD. Vivreon’s preclinical lead, VV7063, represents a novel chemotype with promising early drug-like properties and has no deleterious effect on autonomic or motor function, suggesting CRAC channels are a safe CNS drug target. It inhibits microgliosis by blocking CRAC channel activity with nM potency, suppressing M1-like NF-kB activity, while enhancing M2-like phagocytosis and a homeostatic transcriptional signature. We will now determine the pharmacokinetic (PK) profile of VV7063 in rats followed by testing of VV7063 in a rat model of OUD. The final milestone will be validation of the CRAC channel as a therapeutic target for OUD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2020	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	000	1	2/23/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2020	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	000	1	10/20/2022	NEW	$0
2023	2020	VIVREON BIOSCIENCES LLC	4940 CARROLL CANYON RD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	001	1	1/13/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $55,000 )
2021	2021	VIVREON BIOSCIENCES, LLC	4940 CARROLL CANYON RD STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	001	1	4/19/2021	SUPPLEMENT FOR EXPANSION	$55,000
2021	2020	VIVREON BIOSCIENCES, LLC	4940 CARROLL CANYON RD STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	000	1	3/24/2021	NEW	$0
														Subtotal = $55,000

Issue Date FY: 2020 ( Subtotal = $349,967 )
2020	2020	VIVREON BIOSCIENCES, LLC	4940 CARROLL CANYON RD STE 110	SAN DIEGO	CA	92121	SAN DIEGO	USA	Drug Use and Addiction Research Programs	000	1	9/22/2020	NEW	$349,967
														Subtotal = $349,967

Grand Total All Awards = $404,967

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder

Award Number: R43DA053010

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer